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Background: The aim of our study is to test procalcitonin (PCT) as surrogate marker of identification of Candida
spp. by blood culture (BC) and real-time-polymerase chain reaction (PCR), whether alone or in association with
bacteria, in septic patients.
Methods: We performed a single-centre retrospective study. We reviewed the clinical charts of patients with a diagnosis
of severe sepsis or septic shock treated at our general intensive care unit from March 2009 to March 2013. We analysed
all diagnostic episodes consisting of BC, real-time PCR assay and dosage of PCT. We registered age, sex, white blood
count, sequential organ failure assessment score and type of admission between medical or surgical. When inclusion
criteria were met more than once, we registered the new diagnostic episode as subsequent diagnostic episode. The
diagnostic performance of PCT to predict Candida spp. identification alone or in mixed infections by either BC or
PCR was tested using the receiver-operative characteristic curve. Logistic regression was constructed using presence
of Candida spp. as the dependent variable.
Results: A total of 260 diagnostic episodes met the inclusion criteria. According to BC results classification, a significantly
lower value of PCT was observed in Candida spp. BSI (0.99 ng/ml, 0.86 - 1.34) than in BSI caused by bacteria (16.7 ng/ml,
7.65 - 50.2) or in mixed infections (4.76 ng/ml, 2.98 - 6.08). Similar findings were observed considering PCR results.
A cut-off of≤ 6.08 ng/ml for PCT yielded a sensitivity of 86.8%, a specificity of 87.4%, a positive predictive value of
63.9%, a negative predictive value (NPV) of 96.3% and an area under the curve of 0.93 for Candida spp. identification
by BC. A similar high NPV for a cut-off≤ 6.78 ng/ml was observed considering the classification of diagnostic episodes
according to PCR results, with an AUC of 0.85. A subsequent diagnostic episode was independently associated with
Candida spp. detection either by BC or PCR.
Conclusion: PCT could represent a useful diagnostic tool to exclude the detection of Candida spp. by BC and PCR in
septic patients.
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Candida species (spp.) are currently among the leading
microorganisms causing bloodstream infection (BSI) in
critically ill patients worldwide. They are responsible for
high crude mortality and healthcare costs [1-3]. A delay
in starting adequate antifungal treatment is an inde-
pendent predictor of high in-hospital mortality [4-6].
Nonetheless, BC requires several days for Candida spp.
detection and it is still the gold standard for microbio-
logical diagnosis [7-9]. β-1,3-D-glucan and mannan anti-
gen in association with anti-mannan antibodies have been
recently recommended as surrogate markers of Candida
spp. infection [7,10]. However, their use has several lim-
itations [7,11-15]. Polymerase chain reaction (PCR) is
an alternative method to promptly identify DNA of
microorganisms but its diagnostic performance in fungal
infections is still questioned [7,16,17]. Procalcitonin (PCT)
is widely used as marker of bacterial infection [18-20] and
as guide to reduce patients’ exposure to antibiotics [21].
Few data support its usefulness as a surrogate marker for
Candida spp. infection [22-24]. However, its value in
patients with a mixed infection sustained by both bacteria
and Candida spp., have not been investigated. Further-
more, no studies have described the correlation between
PCT value and identification of Candida spp. DNA by
PCR. The aim of our study is to test PCT as surrogate
marker of Candida spp. detection by BC or PCR whether
alone or in association with bacteria in septic patients.
Methods
We obtained the approval from our institutional review
board (Comitato Bioetico AOUP “P. Giaccone”, Palermo,
Italy) for this single - centre retrospective study. In-
formed consent was waived due to the retrospective and
anonymous nature of data collection and analysis. We
reviewed the clinical records of all patients with a diag-
nosis of severe sepsis or septic shock [25] from March
2009 to March 2013 at the general Intensive Care Unit
of the University Hospital “P. Giaccone”, Palermo, Italy.
We analysed the diagnostic episodes performed after the
diagnosis of severe sepsis or septic shock and registered
those in agreement with our diagnostic protocol consist-
ing of a blood culture, a PCR assay for microorganism
detection (bacteria and/or Candida spp.) and a dosage of
PCT. We excluded the diagnostic episodes done on
patients with known immunodeficiency not related to
sepsis, those with missing tests and those not completed
within a 8-hour time interval. For each complete diag-
nostic episode, we registered age, sex, white blood count
(WBC), Sequential Organ Failure Assessment (SOFA)
score [26] and type of admission of the corresponding
patient. The admission was considered as surgical if
patient underwent surgery within 30 days preceding the
ICU admission, otherwise it was considered as medical.According to the results of each microbiological test, the
diagnostic episodes were then classified in four groups:
bacterial infection, mixed infection (bacterial infection and
Candida spp. infection), Candida infection and negative.
We also subdivided the bacterial and mixed BSI according
to Gram staining. When inclusion criteria were met more
than once for a single patient during the ICU admission
(i.e. new BSI documented by BC and PCR completed
by a PCT determination), we considered this event a
new diagnostic episode for data analysis. Neverthe-
less, we registered the event as subsequent diagnostic
episode. In our ICU, a set of three blood specimens is
drawn from each patient for BC, according to the re-
cently published guidelines of the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID)
[7]. We considered only blood specimens collected through
venipuncture. A blood specimen of 5 ml is collected in a
EDTA test tube for PCR analysis. We excluded the
diagnostic episode from the analysis if a violation of the
protocol for sterile procedures was encountered during
clinical records review. In our institution, BACTEC®
9050 system (Becton Dickinson Diagnostic Instrument
System, Paramus, NJ, USA) is used for the first step
of blood culture process. A multiplex real time PCR
(LightCycler Septifast®, MGRADE®, Roche Molecular
Diagnostics, Prague, Czech Republic) is adopted as add-
itional diagnostic tool for detection of the 25 most com-
mon pathogens causing BSI in our general ICU. This
PCR assay is able to identify 5 Candida species (albicans,
parapsilosis, tropicalis, krusei, glabrata). PCT is dosed
by immunoassay through the Kriptor® PCT (Brahms,
Hennigsdorf, Germany). Primary outcome of the study
was to assess PCT median values in septic patients with a
BSI caused by Candida spp. and/or bacteria detected by
BC/PCR. Secondary outcome was the evaluation of the
diagnostic performance of PCT with the identification of
its sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) for detection of
Candida spp.
Statistical analysis
Variables distribution was analyzed by D’Agostino-
Pearson’s test. For variables with normal distribution, we
calculated and reported mean and standard deviation.
Variables without a normal distribution were expressed
as median and interquartile ranges (25th-75th) and
comparisons were performed through Mann–Whitney
U-test. One-way-analysis of variance ANOVA was used to
test the difference between the means of different sub-
groups variables. Prior to ANOVA test, Levene’s test for a
quality of variances was performed. If the ANOVA test was
positive, we performed a Student-Newman-Keuls test or
pairwise comparison of subgroups. The Kruskall-Wallis test
(H-test) was used to analyse the effect of a classification
Table 1 Diagnostic episodes classification according to
BC and PCR results
Blood culture results
Bacteria Mixed Negative Candida Total
N° 151 31 56 22 260
PCR results
Bacteria Mixed Negative Candida Total
N° 143 39 48 30 260
For differentiation of Bacteria according to Gram staining, see text.
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was not normal. For post-hoc analysis, if the Kruskall-
Wallis test was positive, we performed a test for pairwise
comparison of subgroups according to Conover [27]. A fre-
quency table was constructed and the chi-square test was
adopted for comparison of proportions. The diagnostic per-
formance of PCT to predict the identification of Candida
spp. by either BC or PCR was tested using the receiver-
operating characteristic (ROC) curves. We calculated the
area under the ROC curves (AUC) and the values with the
highest Youden index (best PCT cut-offs). Logistic regres-
sion analysis was performed with presence of Candida spp.
(Candidemia) as the dependent variable whether alone or
in association with bacteria. The power of the calculated
model was tested by Hosmer - Lemeshow goodness of fit
test. A variable was entered into the model if its associated
significance level was p < 0.05. On the contrary, variables
were removed from the model if p > 0.1. Then, significant
variables were sequentially entered into the model, checking
and possibly removing variables as they became not
significant (stepwise method). Regression coefficients
(β coefficient) were calculated and reported. A value of
p < 0.05 was considered statistically significant. Statistical
analysis was performed using MedCalc for Windows,
version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium).
Results
A total of 321 severe sepsis/septic shock patients were
admitted to our ICU during the study period, accountingFigure 1 Flow-chart of the study.for a total of 424 diagnostic episodes. Among them, 260
fulfilled the adopted inclusion criteria (Figure 1). BC
detected 151 BSI caused by bacteria (18 caused by
Gram +, 32 by Gram + and Gram -, 101 by Gram -), 22 by
Candida spp., 31 mixed infection sustained by both bac-
teria and Candida spp. (5 Candida spp. and Gram +, 26
Candida spp. and Gram -) and 56 negative specimens. Ac-
cording to PCR results, 143 BSI were caused by bacteria
spp., (25 caused by Gram +, 27 by Gram + and Gram -, 91
by Gram -), 30 by Candida spp., 39 by a mixed infection
(8 Candida spp. and Gram +, 31 Candida spp. and Gram -)
and 48 were negative (Table 1).
Demographic data and characteristics of all diagnostic
episodes are showed in Tables 2 and 3 for BC and PCR
results respectively. A higher proportion of surgical
patients was detected in Candida spp. BSI than in those
caused by bacteria (p = 0.05) or negative (p = 0.03) accord-
ing to BC results. With regard to infections demonstrated
Table 2 Demographic data for BC diagnostic episodes
Bacteremia (1) Mixed (2) Negative (3) Candida (4) Overall P value
Diagnostic episodes 151 31 56 22 260
Age Mean (SD) 65.3 (13.9) 67.1 (14.1) 65.2 (13.4) 68.8 (11.7) 65.8 (13.6) 0.66
Sex (male) (%) 79 (52.3) 17 (54.9) 32 (57.1) 11 (50) 139 (53.5) 0.92
WBC (cells x103/μL)
Median (I.Q)
16.1 (14.1-18.2) 17.2 (14.2-18.3) 16.1 (13.0-18.1) 16.9 (14.9 -18.5) 16.2 (13.9-18.2) 0.24
SOFA Mean (SD) 7.8 (1.4) 7.9 (2.1) 7.6 (1.1) 8.2 (1.6) 7.8 (1.5) 0.5
Surgical (%) 90 (59.6) 20 (64.5) 29 (51.8) 3 vs 4 p = 0.03 19 (86.4) 1 vs 4 p = 0.05 158 (60.8) 0.04
Septic Shock (%) 52 (34.4) 9 (29) 15 (26.8) 7 (31.8) 83 (31.9) 0.74
Subsequent Diagnostic
Episode (%)
40 (26.5) 21 (66.7) 1 vs 2 p = 0.0057 15 (26.8) 3 vs 4 p = 0.0048 18 (81.8) 1 vs 4 p = 0.0003 94 (36.2) 0.0001
ANOVA test for comparisons of means. Kruskall – Wellis test for comparisons of medians.
SD standard deviation, I.Q. interquartile range.
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sodes was encountered in Candida spp. BSI and mixed BSI
(p = 0.0001). Similar results were found according to PCR
classification. PCT values are showed in Table 4 for BC
and in Table 5 for PCR results. Considering BC results, a
significantly lower value of PCT was observed in Candida
spp. BSI (0.99 ng/ml, 1.34 - 0.86) than in BSI caused by
bacteria (16.7 ng/ml, 50.2 - 7.65) or in mixed infections
(4.76 ng/ml, 6.08 – 2.98) (Figure 2). Similar findings were
observed when diagnostic episodes were classified accord-
ing to PCR results (Figure 3).
A cut-off of 6.08 ng/ml for PCT showed a sensitivity
of 86.8%, a specificity of 87.4%, a PPV of 63.9%, a NNP
of 96.3% and an AUC of 0.93 for identification of
Candida spp. (alone or in association with bacteria) by BC
(Figure 4). Similarly, according to PCR results, a cut-off of
6.78 ng/ml yielded a sensitivity of 73.9%, a specificity of
81.7%, a PPV of 59.3%, a NPV of 89.7 and an AUC of 0.85
(Figure 5).
The variables included in the logistic regression model
were the value of PCT and the subsequent diagnostic
episodes, which both resulted independently associatedTable 3 Demographic data for PCR diagnostic episodes
Bacteremia (1) Mixed (2)
Diagnostic episodes 143 39
Age Mean (SD) 65.2 (13.8) 67.1 (14.3)
Sex (male) (%) 74 (51.7) 20 (51.3)
WBC (cells x103/μL) Median (I.Q) 16.1 (13.9 -18.2) 16.9 (14.4-18.2)
SOFA Mean (SD) 7.8 (1.4) 8.1 (2.0)
Surgical (%) 87 (60.8) 22 (56.4)
Septic Shock (%) 52 (36.4) 9 (23.1)
Subsequent Diagnostic Episode % 38 (26.6) 23 (58.9)1 vs 2 p = 0.0
ANOVA test for comparisons of means. Kruskall – Wellis test for comparisons of me
SD standard deviation, I.Q. interquartile range.with the presence of Candida spp. detected by either BC
or PCR (Tables 6 and 7 respectively).
The different Candida spp. isolated by BC and PCR
are shown in Tables 8 and 9.
PCT values did not differ between Candida albicans
and non-albicans species isolated by BC (p = 0.36) and
PCR (p = 0.25).
Discussion
A prompt start of effective antifungal therapy is essential
for mortality reduction in Candida spp. BSI [4,5]. Even if
BC is the cornerstone for diagnosis of Candida spp. BSI,
concern has been raised about the long time required
before microbiological response [28,29]. A pre-emptive
approach aims to start treatment without delay in
patients with clinical and microbiological evidence of
candidemia without its definitive BC-based proof, while
limiting the use of antifungal agents in low-risk patients
[9,28,30,31]. Surrogate markers of candidemia were studied
for this purpose. β-1,3–D – glucan is not specific for
Candida spp. BSI as it is considered a panfungal diagnostic
method [7,14]. Despite a high negative predictive value,Negative (3) Candida (4) Overall P value
48 30 260
64.3 (13.1) 69.2 (11.3) 65.8 (13.5) 0.37
28 (58.3) 16 (53.3) 138 (53.1) 0.87
16.4 (13.0 -18.1) 16.7 (14.2 -18.4) 16.2 (13.9-18.2) 0.58
7.6 (1.1) 8.0 (1.4) 7.8 (1.5) 0.3
25 (52.1) 24 (80.0) 158 (60.8) 0.09
15 (31.2) 7 (23.3) 83 (31.9) 0.29
2 14 (29.2) 19 (63.3) 1 vs 4 p = 0.02 94 (36.2) 0.0001
dians.
Figure 2 Box-plot distribution of PCT values according to BC
classification of diagnostic episodes.
Table 4 Procalcitonin values according to the classification
of BC results
Group PCT (ng/ml) Median (I.Q.) Different (p < 0.05) from
Bacteremia 16.75 (7.65 - 50.5) Mixed, Candidemia
Mixed 4.76 (2.98 - 6.08) Bacteremia, Negative,
Candidemia
Negative 12.36 (9.36 - 37.2) Mixed, Candidemia
Candidemia 0.99 (0.86 - 1.34) Bacteremia, Mixed, Negative
I.Q. interquartile range.
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and interventions (i.e. albumin or immunoglobulin admin-
istration, hemodialysis) are responsible for its reported low
specificity [7,11,13,14,32]. The use of surgical gauzes con-
taining glucan may increase β-1,3–D – glucan level leading
to false positive results and to its poor reliability in ICU
with a high admission rate of surgical patients [12,33,34].
The combined determination of mannan and anti-mannan
antibodies in serum is a specific diagnostic marker of
Candida spp. detection with a high negative predictive
value [10,15,35,36]. Serial determinations are needed to
optimise the diagnostic performance of both β-1,3–D –
glucan and mannan/anti-mannan antibodies leading to
the high related costs. Concerning PCR techniques as
diagnostic tool for Candida spp. BSI, one of the most im-
portant limits precluding the widespread adoption is the
potential contamination with clinically not significant
fungal DNA [16]. Moreover, PCR-based molecular tech-
niques require technical skills and equipment. Further
studies are needed to assess their diagnostic performance
and harmonization of results according to the adopted
PCR-technique [7,16]. Few data support the usefulness of
PCT as surrogate marker of Candida spp. BSI. [22-24,37]
and no studies have investigated PCT values in patients
with BSI caused by both Candida spp. and bacteria.
Moreover, the diagnostic performance of PCT has been
investigated in light of the BC results and not considering
the results of a real-time PCR technique. In this study,
we tested PCT as surrogate marker of identification of
Candida spp. by BC or PCR whether alone or in associ-
ation with bacteria in septic patients. We identified a cut-
off for PCT level useful to rule out the presence ofTable 5 Procalcitonin values according to the classification
of PCR results
Group PCT (ng/ml) Median (I.Q.) Different (p < 0.05) from
Bacteremia 16.54 (7.83 - 47.8) Mixed, Candidemia
Mixed 6.08 (4.29 - 12.65) Bacteremia, Negative,
Candidemia
Negative 13.4 (9.36 - 41.5) Mixed, Candidemia
Candidemia 1.27 (0.92 - 2.09) Bacteremia, Mixed, Negative
I.Q. interquartile range.Candida spp. with a high negative predictive value. The
finding of a significantly lower PCT level in Candida spp.
BSI than in bacterial BSI is consistent with that previ-
ously reported [22-24]. According to our data, in BSI
caused by both Candida spp. and bacteria, the PCT
showed a higher level than in BSI caused only by Candida
spp. but a lower level than in bacterial and negative BSI.
Of note, Candida spp. infection was diagnosed as a sec-
ond BSI in a relevant number of cases, confirming previ-
ously published data [23]. This finding may be explained
in light of the novel recognition of sepsis as a complex
immune response to pathogens with a hyperinflamma-
tory phase as a hallmark of the early period followed by a
phase of impaired immunity and an anti - inflammatory
phase predominance. Due to this susceptibility, a second-
ary nosocomial infection such as Candida spp. infection,
typically occurs [38-41]. It may be hypothesized that the
observed low PCT level in relation to Candida spp.Figure 3 Box-plot distribution of PCT values according to PCR
classification of diagnostic episodes.
Figure 4 ROC curve of PCT for prediction of identification of Candida spp. by BC. C.I = confidence interval; PPV = positive predictive value;
NPV = negative predictive value; AUC = area under the curve.
Figure 5 ROC curve of PCT for prediction of identification of Candida spp. by PCR. C.I = confidence interval; PPV = positive predictive
value; NPV = negative predictive value; AUC = area under the curve.
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Table 6 Logistic regression Candidemia
Variable Variable
type
β coefficient Standard
error
P value
PCT Continuos −0.41 0.07 < 0.0001
Subsequent
Diagnostic episode
Dichotomous 2.23 0.48 < 0.0001
Variables not included in the model: age, sex, SOFA score, Surgical, WBC,
Septic Shock. (Hosmer & Lemeshow test: chi-square: 4.49, p = 0.81).
Table 8 Candida spp. detected (according to BC results)
and their PCT values (median)
Candida spp Diagnostic
episodes (%)
PCT value
Median (I.Q.)
C. Albicans 13 (59.0) 1.32 (0.92 - 2.0)
C. non albicans 9 (41.0) 0.92 (0.68 - 1.98)
C. Parapsilosis 6 (27.3) 0.90 (0.83 - 1.29)
C. glabrata 1 (4.5) 2.98
C. krusei 2 (9.1) 1.58 (0.12 - 3.05)
C. tropicalis 0
I.Q. interquartile range.
Albicans vs non albicans p = 0.36.
Table 9 Candida spp. detected (according to PCR results)
and their PCT values (median)
Candida spp Diagnostic episodes (%) PCT value Median (I.Q.)
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http://www.biomedcentral.com/1471-2253/14/9infection may reflect this impaired immunity phase of
sepsis or rather may result from a different inflammatory
pattern stimulated by fungal infection [23,42]. Indeed, a
lower level of PCT was observed in patients with a subse-
quent BSI than in those experiencing the first BSI, re-
gardless of the identification of Candida spp. as the
responsible organism for the subsequent BSI [42]. Thus,
identification of PCT level in the case of a mixed infec-
tion is important since intensivists encounter a growing
number of critically ill patients in immunoparalysis prone
to Candida spp. infection and a promptly anti-fungal
therapy institution is pivotal for mortality reduction
[4,38]. Indeed, a high number of Candida spp. are de-
tected in association with a bacterial infection, namely by
gram negative species, in daily practice of our ICU with
its high number of surgical patients. The high negative
predictive value of PCT for detection of Candida spp. by
either BC or PCR may represent a useful tool to exclude
the presence of candidemia and guide the antifungal
treatment regimens in critically ill patients, with the ad-
vantage, among others, of costs reduction. [43] In our
opinion, the limitations of the study are its retrospective
design and the low number of Candida spp. BSI analysed,
which reflects the low, though increasing, prevalence of
Candida spp. BSI [3,44,45]. Another limitation may ori-
ginate from the characteristic epidemiology of pathogens
causing BSI in our general ICU with a high admission
rate of surgical patients. Among them we observe the
predominance of the abdominal surgical patient who fre-
quently underwent an emergency procedure. This setting
leads to the high prevalence of Gram negative pathogens
in our population as responsible for BSI, either alone or
in association with Candida spp. [1,46,47]. However, pa-
tients with complicated abdominal surgery (i.e. secondary
peritonitis) are at high risk of Candida spp. BSI and this
population would benefit from a validated marker for thisTable 7 Logistic regression PCR
Variable Variable
type
β coefficient Standard
error
P value
PCT Continuos −0.07 0.016 < 0.0001
Subsequent
Diagnostic episode
Dichotomous 1.38 0.33 < 0.0001
Variables not included in the model: age, sex, SOFA score, Surgical, WBC,
Septic Shock. (Hosmer & Lemeshow test: chi-square: 99.7, p < 0.0001).kind of infection [48]. Previous studies reported a higher
level of PCT for Gram negative BSI than in patients with
a BSI caused by a Gram positive infection, leading to the
conclusion that PCT may represent a useful tool in dif-
ferentiating Gram positive from Gram negative BSI.
Nevertheless, this study was not designed to reach this
goal. In our opinion, it is unlikely that Gram positive bac-
teria could have influenced PCT values both in bacterial
and mixed BSI, given their low prevalence. Finally, differ-
ent data show the higher sensitivity of home-made PCR
compared to non home-made PCR techniques for fungal
species detection [17]. The lower diagnostic performance
of PCT - analysed for PCR results prediction (Figure 5) -
may be explained by the lower specificity for living yeast
since PCR technique aims at identifying solely pathogen
DNA molecules. Nevertheless, BC is still considered the
gold standard for comparison of alternative diagnostic
methods [7] and our results may be interpreted in light
of BC findings.
Conclusions
According to our data, PCT determination represents a
useful diagnostic tool to exclude the presence of Candida
spp. in BSI of critically ill patients. It may be adopted as
a component of a diagnostic strategy aiming to limit the
unwarranted use of antifugal agents.C. Albicans 14 (46.7) 1.32 (0.97 - 2.29)
C. non albicans 16 (53.3) 1.08 (0.86 - 1.60)
C. Parapsilosis 10 (33.3) 0.92 (0.84 - 1.20)
C. glabrata 3 (10) 2.09 (1.21 - 2.98)
C. krusei 2 (6.7) 1.58 (0.12 – 3.05)
C. tropicalis 1 (3.3) 1.56
I.Q. interquartile range.
Albicans vs non albicans p = 0.25.
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 Procalcitonin shows a high negative predictive value
for detection of Candida spp. by blood culture or
polymerase chain reaction either alone or in a mixed
infection with bacteria.
 Procalcitonin may represent a useful tool for the
diagnostic workup of critically ill patients with
Candida bloodstream infections.
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